• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

月经过多干预研究中结果报告的差异:一项系统评价

Variation of outcome reporting in studies of interventions for heavy menstrual bleeding: a systematic review.

作者信息

Cooper N A M, Papadantonaki R, Yorke S, Khan K S

出版信息

Facts Views Vis Obgyn. 2022 Sep;14(3):205-218. doi: 10.52054/FVVO.14.3.030.

DOI:10.52054/FVVO.14.3.030
PMID:36206795
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10350948/
Abstract

BACKGROUND

Heavy menstrual bleeding (HMB) detrimentally effects women. It is important to be able to compare treatments and synthesise data to understand which interventions are most beneficial, however, when there is variation in outcome reporting, this is difficult.

OBJECTIVES

To identify variation in reported outcomes in clinical studies of interventions for HMB.

MATERIALS AND METHODS

Searches were performed in medical databases and trial registries, using the terms 'heavy menstrual bleeding', menorrhagia*, hypermenorrhoea*, HMB, "heavy period "period", effective*, therapy*, treatment, intervention, manage* and associated MeSH terms. Two authors independently reviewed and selected citations according to pre-defined selection criteria, including both randomised and observational studies. The following data were extracted- study characteristics, methodology and quality, and all reported outcomes. Analysis considered the frequency of reporting.

RESULTS

There were 14 individual primary outcomes, however reporting was varied, resulting in 45 specific primary outcomes. There were 165 specific secondary outcomes. The most reported outcomes were menstrual blood loss and adverse events.

CONCLUSIONS

A core outcome set (COS) would reduce the evident variation in reporting of outcomes in studies of HMB, allowing more complete combination and comparison of study results and preventing reporting bias.

WHAT IS NEW?: This in-depth review of past research into heavy menstrual bleeding shows that there is the need for a core outcome set for heavy menstrual bleeding.

摘要

背景

月经过多对女性有不利影响。能够比较各种治疗方法并综合数据以了解哪些干预措施最有益是很重要的,然而,当结果报告存在差异时,这就变得困难了。

目的

确定月经过多干预措施临床研究中报告结果的差异。

材料与方法

在医学数据库和试验注册库中进行检索,使用的检索词有“月经过多”“月经过多*”“经量过多*”“HMB”“月经量多”“经期”“有效*”“治疗*”“疗法”“治疗”“干预”“管理*”以及相关的医学主题词。两位作者根据预先定义的选择标准独立审查并选择文献,包括随机对照研究和观察性研究。提取以下数据——研究特征、方法和质量,以及所有报告的结果。分析考虑报告的频率。

结果

有14个单独的主要结局,但报告情况各不相同,产生了45个具体的主要结局。有165个具体的次要结局。报告最多的结局是月经失血和不良事件。

结论

一个核心结局集(COS)将减少月经过多研究中结局报告的明显差异,使研究结果能够更完整地合并和比较,并防止报告偏倚。

新发现是什么?:对过去月经过多研究的深入综述表明,需要一个月经过多的核心结局集。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9908/10350948/5b7e340db362/FVVinObGyn-14-205-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9908/10350948/5b7e340db362/FVVinObGyn-14-205-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9908/10350948/5b7e340db362/FVVinObGyn-14-205-g001.jpg

相似文献

1
Variation of outcome reporting in studies of interventions for heavy menstrual bleeding: a systematic review.月经过多干预研究中结果报告的差异:一项系统评价
Facts Views Vis Obgyn. 2022 Sep;14(3):205-218. doi: 10.52054/FVVO.14.3.030.
2
Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.用于治疗月经过多的孕激素或释放孕激素的宫内节育系统。
Cochrane Database Syst Rev. 2015 Apr 30(4):CD002126. doi: 10.1002/14651858.CD002126.pub3.
3
Progestogen-releasing intrauterine systems for heavy menstrual bleeding.含孕激素的宫内节育系统用于治疗月经过多。
Cochrane Database Syst Rev. 2020 Jun 12;6(6):CD002126. doi: 10.1002/14651858.CD002126.pub4.
4
Cyclical progestogens for heavy menstrual bleeding.用于治疗月经过多的周期性孕激素
Cochrane Database Syst Rev. 2019 Aug 14;8(8):CD001016. doi: 10.1002/14651858.CD001016.pub3.
5
Combined hormonal contraceptives for heavy menstrual bleeding.复方激素避孕药用于治疗月经过多
Cochrane Database Syst Rev. 2019 Feb 11;2(2):CD000154. doi: 10.1002/14651858.CD000154.pub3.
6
Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding.子宫内膜切除术和消融术与子宫切除术治疗月经过多的比较
Cochrane Database Syst Rev. 2019 Aug 29;8(8):CD000329. doi: 10.1002/14651858.CD000329.pub3.
7
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
8
Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding.子宫内膜切除术和消融术与子宫切除术治疗月经过多的比较
Cochrane Database Syst Rev. 2013 Nov 29(11):CD000329. doi: 10.1002/14651858.CD000329.pub2.
9
Interventions for heavy menstrual bleeding; overview of Cochrane reviews and network meta-analysis.干预重度月经过多;Cochrane 综述和网络荟萃分析概述。
Cochrane Database Syst Rev. 2022 May 31;5(5):CD013180. doi: 10.1002/14651858.CD013180.pub2.
10
Non-surgical interventions for treating heavy menstrual bleeding (menorrhagia) in women with bleeding disorders.对患有出血性疾病的女性进行非手术干预以治疗月经过多(月经过多)。
Cochrane Database Syst Rev. 2016 Nov 10;11(11):CD010338. doi: 10.1002/14651858.CD010338.pub3.

引用本文的文献

1
Outcome reporting for heavy menstrual bleeding.月经过多的结局报告
Facts Views Vis Obgyn. 2022 Sep;14(3):201-203. doi: 10.52054/FVVO.14.3.031.

本文引用的文献

1
A systematic review of outcome reporting and outcome measures in studies investigating uterine-sparing treatment for adenomyosis.一项关于子宫腺肌病保留子宫治疗研究中结局报告和结局指标的系统评价。
Hum Reprod Open. 2021 Aug 7;2021(3):hoab030. doi: 10.1093/hropen/hoab030. eCollection 2021.
2
RoB 2: a revised tool for assessing risk of bias in randomised trials.《随机对照试验偏倚风险评估工具2:修订版》
BMJ. 2019 Aug 28;366:l4898. doi: 10.1136/bmj.l4898.
3
Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial.
Elagolix 单药治疗或加用激素补充治疗伴有月经过多和子宫肌瘤的女性:一项随机对照试验。
Obstet Gynecol. 2018 Nov;132(5):1252-1264. doi: 10.1097/AOG.0000000000002933.
4
Efficacy and Safety of Estradiol Valerate/Dienogest for the Management of Heavy Menstrual Bleeding: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase III Clinical Trial.戊酸雌二醇/地诺孕素治疗月经过多的有效性和安全性:一项多中心、双盲、随机、安慰剂对照、III 期临床试验。
J Womens Health (Larchmt). 2018 Oct;27(10):1225-1232. doi: 10.1089/jwh.2017.6522. Epub 2018 Jun 29.
5
Effect of Hydroalcoholic Extracts of Capsella Bursa-Pastoris on Heavy Menstrual Bleeding: A Randomized Clinical Trial.荠苨水醇提取物治疗月经过多的随机临床试验。
J Altern Complement Med. 2018 Jul;24(7):694-700. doi: 10.1089/acm.2017.0267. Epub 2018 Mar 20.
6
Medical therapy versus radiofrequency endometrial ablation in the initial treatment of heavy menstrual bleeding (iTOM Trial): A clinical and economic analysis.医学治疗与射频子宫内膜消融术治疗月经过多的初始治疗(iTOM试验):一项临床与经济学分析。
PLoS One. 2017 Nov 15;12(11):e0188176. doi: 10.1371/journal.pone.0188176. eCollection 2017.
7
Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study.Elagolix 治疗子宫肌瘤相关重度月经过多的 2a 期概念验证研究结果。
Fertil Steril. 2017 Jul;108(1):152-160.e4. doi: 10.1016/j.fertnstert.2017.05.006. Epub 2017 Jun 1.
8
A Randomized Controlled Multicenter US Food and Drug Administration Trial of the Safety and Efficacy of the Minerva Endometrial Ablation System: One-Year Follow-Up Results.一项关于米涅瓦子宫内膜消融系统安全性和有效性的随机对照多中心美国食品药品监督管理局试验:一年随访结果
J Minim Invasive Gynecol. 2017 Jan 1;24(1):124-132. doi: 10.1016/j.jmig.2016.09.009. Epub 2016 Sep 26.
9
The SONATA Study: Sonography-Guided Transcervical Ablation of Uterine Fibroids.
J Minim Invasive Gynecol. 2015 Nov-Dec;22(6S):S41. doi: 10.1016/j.jmig.2015.08.113. Epub 2015 Oct 15.
10
Randomized controlled trial of thermal balloon ablation versus vaginal hysterectomy for leiomyoma-induced heavy menstrual bleeding.热球囊消融术与经阴道子宫切除术治疗子宫肌瘤所致月经过多的随机对照试验
Int J Gynaecol Obstet. 2016 Nov;135(2):140-144. doi: 10.1016/j.ijgo.2016.04.020. Epub 2016 Aug 5.